The role of cyclic adenosine monophosphate in the suppression of cellular immunity after thermal injury.
OBJECTIVE
Cyclic adenosine monophosphate (cAMP) is an intracellular second messenger that is known to convey inhibitory signals for T-cell proliferation and function. We investigated the association between this molecule and the profound immunosuppression that accompanies thermal injury.


METHODS
Mice were randomized into two groups: one group was subjected to a 20% full-thickness scald burn; the second to a sham burn (control). The mice were killed on days 4, 7, or 10 after the burn injury and splenocytes were pooled and cultured for 15 minutes in the presence or absence of prostaglandin E2 (PGE2).


RESULTS
Levels of cAMP in splenocytes were significantly elevated on day 7 after burn in the burn group compared with the sham controls (P < .05, Wilcoxon Rank Sum Test). Incubation of splenocytes with PGE2 resulted in significantly greater levels of intracellular cAMP in cells from the burn group compared with controls on days 4, 7, and 10. Incubation of normal splenocytes with dibutyryl cAMP in the presence of concanavalin A significantly decreased cell proliferation and the production of interleukin-2. The decrease in interleukin-2 production was evident at the level of messenger RNA expression. Stimulation of splenocytes with a combination of phorbol ester and calcium ionophore, bypassing all membrane-associated events prior to protein kinase C activation, reversed the inhibitory effects of dibutyryl cAMP. Incubation of splenocytes from burned animals with H-8, a selective inhibitor of cAMP-dependent protein kinases, restored the proliferative response to that of sham controls on days 4, 7, and 10 after thermal injury.


CONCLUSIONS
These data indicate that elevated levels of intracellular cAMP, combined with an increased production of cAMP in response to circulating PGE2, may play a fundamental role in suppression of the immune response following thermal injury and that cAMP exerts its immunomodulatory effects prior to protein kinase C activation.
Horgan
A F
AF
Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass.
O'Riordain
D S
DS
Chin
D H
DH
Mannick
J A
JA
Rodrick
M L
ML
D000818:Animals; D002056:Burns / Q000276:immunology*; D003208:Concanavalin A / Q000276:immunology; D000242:Cyclic AMP / Q000032:analysis / Q000276:immunology*; D015232:Dinoprostone / Q000276:immunology; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D007108:Immune Tolerance / Q000276:immunology*; D007111:Immunity, Cellular / Q000276:immunology; D007376:Interleukin-2 / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010703:Phorbol Esters; D012333:RNA, Messenger / Q000032:analysis; D011897:Random Allocation; D013154:Spleen / Q000737:chemistry / Q000166:cytology / Q000276:immunology
D007376:Interleukin-2; D010703:Phorbol Esters; D012333:RNA, Messenger; D003208:Concanavalin A; D000242:Cyclic AMP; D015232:Dinoprostone